Skip to Content

Gene Biotherapeutics Inc CRXM

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Gene Biotherapeutics Inc, formerly known as Taxus Cardium Pharmaceuticals Group Inc is an operating company which manages medical technologies portfolio. Its investment portfolio includes Angionetics, which focuses on late-stage clinical development and commercialization of Generx, an angiogenic gene therapy product candidate designed for medical treatment of myocardial ischemia and refractory angina; Activation Therapeutics focuses on the development and commercialization of the Excellagen, which is a flowable dermal matrix technology platform for small molecule drugs, proteins, and biologics.

Contact
11568 Sorrento Valley Road, Suite 14
San Diego, CA, 92121
T +1 858 436-1000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2017
Fiscal Year End Dec 31, 2017
Stock Type Distressed
Employees 6